Shen Chen, Wang Xue-Feng, Wu Xiao-Ti, Liu Xin-Xin, Robinson Nicola, Liu Jian-Ping
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, PR China.
Institute of Health and Social Care, London South Bank University, London, UK.
Integr Med Res. 2026 Mar;15(1):101223. doi: 10.1016/j.imr.2025.101223. Epub 2025 Aug 10.
Burning mouth syndrome (BMS) lacks optimal treatments. This systematic review assessed , a natural product with anti-inflammatory/antioxidant properties, for managing this chronic pain disorder.
PubMed, the Cochrane Library, EMBASE, Web of Science, Scopus, and four Chinese databases were searched until February, 2025 for randomized controlled trials (RCTs) involving adults with BMS. products alone or in combination with conventional medications were included. Outcomes included pain, symptoms, psychological outcomes and salivary function. The GRADE approach was used to assess evidence certainty.
Six RCTs with 336 participants were included. Compared to vitamin B complex alone, capsules alone significantly improved the pain-intensity-based effective rate (RR 6.00, 95 % CI [1.61, 22.34]). Compared to conventional medicines, capsules with conventional medicines significantly increased subjective pain scores (MD 1.51, 95 % CI [1.19, 1.83]), symptom-based effective rate (RR 1.27, 95 % CI [1.14, 1.42]), daily water intake score (MD 1.32, 95 % CI [1.00, 1.64]), sleep duration score (MD 1.88, 95 % CI [1.61, 2.15]), and decreased anxiety and depression scores, while oral liquid combined with mecobalamin significantly reduced 10-point VAS (MD -1.40, 95 % CI [-2.19, -0.61]) and increased the unstimulated salivary flow rate (USFR).The certainty of evidence was all graded as low.
products may improve pain intensity, symptoms, psychological outcomes, and salivary function in patients with BMS. However, the low certainty of evidence due to study limitations and small sample sizes suggests the need for well-designed, large-scale real-world studies to confirm these findings and establish their clinical applicability.
PROSPERO (CRD420250651920).
灼口综合征（BMS）缺乏理想的治疗方法。本系统评价评估了具有抗炎/抗氧化特性的天然产物[具体产物名称未给出]对这种慢性疼痛疾病的治疗效果。
检索了PubMed、Cochrane图书馆、EMBASE、科学网、Scopus以及四个中文数据库，检索截至2025年2月，查找涉及成年BMS患者的随机对照试验（RCT）。纳入单独使用[具体产物名称未给出]产品或与传统药物联合使用的研究。结局指标包括疼痛、症状、心理结局和唾液功能。采用GRADE方法评估证据的确定性。
纳入了6项随机对照试验，共336名参与者。与单独使用复合维生素B相比，单独使用[具体产物名称未给出]胶囊显著提高了基于疼痛强度的有效率（RR 6.00，95%CI[1.61，22.34]）。与传统药物相比，[具体产物名称未给出]胶囊与传统药物联合使用显著提高了主观疼痛评分（MD 1.51，95%CI[1.19，1.83]）、基于症状的有效率（RR 1.27，95%CI[1.14，1.42]）、每日饮水量评分（MD 1.32，95%CI[1.00，1.64]）、睡眠时间评分（MD 1.88，95%CI[1.61，2.15]），并降低了焦虑和抑郁评分，而[具体产物名称未给出]口服液联合甲钴胺显著降低了10分视觉模拟量表（VAS）评分（MD -1.40，95%CI[-2.19，-0.61]），并提高了非刺激性唾液流速（USFR）。证据的确定性均被评为低。
[具体产物名称未给出]产品可能改善BMS患者的疼痛强度、症状、心理结局和唾液功能。然而，由于研究局限性和样本量小，证据的确定性较低，这表明需要设计良好的大规模真实世界研究来证实这些发现并确定其临床适用性。
PROSPERO（CRD420250651920）。
